Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Journal of the American Medical Association (JAMA)

• Publication date

  2017-07-04

• Fields of study

  Medicine

• Identifiers
  DOI 10.1001/jama.2017.7117PMID 28672317PMCID PMC5817473
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comment on American Diabetes Association. Standards of Medical Care in Diabetes—2017. Diabetes Care 2017;40(Suppl. 1):S1–S135

  2017cited by this paper
• Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes: The SWITCH 1 Randomized Clinical Trial

  2017cited by this paper
• Insulin Degludec Versus Insulin Glargine in Type 1 and Type 2 Diabetes Mellitus: A Meta-Analysis of Endpoints in Phase 3a Trials

  2014cited by this paper
• New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 1)

  2014cited by this paper
• New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Oral Agents and Basal Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 2)

  2014cited by this paper
• New Insulin Glargine 300 Units·mL−1 Provides a More Even Activity Profile and Prolonged Glycemic Control at Steady State Compared With Insulin Glargine 100 Units·mL−1

  2014cited by this paper
• A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance

  2014cited by this paper
• Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society

  2013cited by this paper
• World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.

  2013cited by this paper
• Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials

  2012cited by this paper
• Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady‐state conditions in type 1 diabetes

  2012cited by this paper
• Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.

  2012cited by this paper
• A 1-year, randomized, treat-to-target trial (BEGIN Once Long)

  2012cited by this paper
• Incidence and Cost of Hypoglycemia Among Patients with Type 2 Diabetes in the United States: Analysis of a Health Insurance Database

  2011cited by this paper
• Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes

  2009cited by this paper
• Costs of managing severe hypoglycaemia in three European countries

  2009cited by this paper
• Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy

  2009cited by this paper
• 10-year follow-up of intensive glucose control in type 2 diabetes.

  2008cited by this paper
• How hypoglycaemia can affect the life of a person with diabetes

  2008cited by this paper
• Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial.

  2007cited by this paper
• A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naïve People With Type 2 Diabetes

  2007cited by this paper
• Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration

  2007cited by this paper
• Standards of Medical Care in Diabetes: Response to Power

  2006cited by this paper
• Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes.

  2006cited by this paper
• Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique

  2005cited by this paper
• Clinical trial registration: a statement from the International Committee of Medical Journal Editors.

  2005cited by this paper
• Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia.

  2005cited by this paper
• Frequency and predictors of hypoglycaemia in Type 1 and insulin‐treated Type 2 diabetes: a population‐based study

  2005cited by this paper
• Assessment of the Impact of Fear of Hypoglycemic Episodes on Glycemic and Hypoglycemia Management

  2005cited by this paper
• Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes.

  2004cited by this paper
• The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients.

  2003cited by this paper
• Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.

  2003cited by this paper
• Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use.

  2003cited by this paper
• World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects Revised October 7, 2000

  2001cited by this paper
• Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin.

  2001cited by this paper
• Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.

  2000cited by this paper
• Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo.

  2000cited by this paper
• Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

  2000cited by this paper
• A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes.

  2000cited by this paper
• Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes.

  2000cited by this paper
• Uniform Requirements for Manuscripts Submitted to Biomedical Journals

  1991cited by this paper
• Glycemic thresholds for activation of glucose counterregulatory systems are higher than the threshold for symptoms.

  1987cited by this paper

• The Modern Role of Basal Insulin in Advancing Therapy in People With Type 2 Diabetes

  2025cites this paper
• Therapeutic tailored approach in patients with diabetes, cardiovascular and renal comorbidities: A cardiologist's view.

  2025cites this paper
• The health economics of insulin therapy: How do we address the rising demands, costs, inequalities and barriers to achieving optimal outcomes

  2025cites this paper
• Multi-omics analytics and biosensors to enable digital twin platforms for P4 medicine

  2025cites this paper
• Current trends in insulin therapy.

  2025cites this paper
• Association of triglyceride–glucose index with diabetes or prediabetes in Chinese hypertensive patients: A retrospective cohort study

  2024cites this paper
• Expert Opinion on Current Trends in the Use of Insulin in the Management of People with Type 2 Diabetes from the South-Eastern European Region and Israel

  2024cites this paper
• Effects of insulin glargine U300 versus insulin degludec U100 on glycemic variability, hypoglycemia, and diet evaluated by continuous glucose monitoring in type 1 diabetes: a retrospective cross‐sectional study

  2024cites this paper
• Efficacy and safety of basal insulins in people with type 2 diabetes mellitus: a systematic review and network meta-analysis of randomized clinical trials

  2024cites this paper
• Insulin Analogs and the Mode of Insulin Delivery: Recent Advances and Challenges.

  2024cites this paper
• Pharmacologic Glycemic Management of Type 2 Diabetes in Adults---2024 Update.

  2024cites this paper
• Modern insulin treatment for type 2 diabetes

  2024cites this paper
• Clinical perspectives on the frequency of hypoglycemia in treat-to-target randomized controlled trials comparing basal insulin analogs in type 2 diabetes: a narrative review

  2024influential citation
• Insulin Degludec in People with Type 2 Diabetes in China: A Non-interventional, Retrospective Chart Review Study (CN-TREAT)

  2024cites this paper
• Out of Sight, Out of Mind: A Call to Action for the Treatment of Hypoglycemia

  2024cites this paper
• Once-weekly insulins: a promising approach to reduce the treatment burden in people with diabetes

  2024cites this paper
• The Basis for Weekly Insulin Therapy: Evolving Evidence With Insulin Icodec and Insulin Efsitora Alfa

  2024cites this paper
• Pharmacologic inhibition of somatostatin receptor 2 to restore glucagon counterregulation in diabetes

  2024cites this paper
• Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat-to-target trial.

  2023cites this paper
• Insulinas de ultra larga acción: evaluación de prescripción-indicación en diabéticos tipo 2 de una institución de salud colombiana

  2023cites this paper
• [New Insulins for Type 1 Diabetes treatment].

  2023cites this paper
• Correlation Between Time in Range and HbA1c in People with Type 2 Diabetes on Basal Insulin: Post Hoc Analysis of the SWITCH PRO Study

  2023cites this paper
• Real-World Effects of Second-Generation Versus Earlier Intermediate/Basal Insulin Analogues on Rates of Hypoglycemia in Adults with Type 1 and 2 Diabetes (iNPHORM, US)

  2023cites this paper
• Hypoglycaemia frequency and physiological response after double or triple doses of once-weekly insulin icodec vs once-daily insulin glargine U100 in type 2 diabetes: a randomised crossover trial

  2023cites this paper
• The efficacy of insulin degludec and insulin glargine over NPH insulin among toddlers and preschoolers with type 1 diabetes using glycemic variability and time in range

  2023cites this paper
• Multidisciplinary Panel Consensus for the Management of Patients with Type 2 Diabetes: A Delphi Study.

  2023cites this paper
• Safety and Clinical Outcomes of Insulin Degludec in Korean Patients with Diabetes in Real-World Practices: A Prospective, Observational Study

  2023cites this paper
• The use of long-acting insulin degludec in adult patients with type 2 diabetes mellitus in real clinical practice in Russia

  2023cites this paper
• The Role of Platelets in Hypoglycemia-Induced Cardiovascular Disease: A Review of the Literature

  2023cites this paper
• Use of Second-Generation Basal Insulin Gla-300 in Special Populations: A Narrative Mini-Review

  2023cites this paper
• Human Insulin as an Antidote to the High Cost of Insulin: Clinical Insignificance of Pharmacokinetic/Pharmacodynamic Differences.

  2023cites this paper
• A Relative Cost of Control Analysis of IDegLira versus Other Forms of Basal Insulin Intensification in Mexico

  2023cites this paper
• Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial.

  2023cites this paper
• Efficacy and Tolerability of Insulin Degludec Versus Other Long-acting Basal Insulin Analogues in the Treatment of Type 1 and Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis.

  2022cites this paper
• Comparative efficacy and safety of two fixed ratio combinations in type 2 diabetes mellitus patients previously poorly controlled on different insulin regimens: a multi-centric observational study.

  2022cites this paper
• 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2023.

  2022cites this paper
• Glucose-responsive nanoparticles designed via a molecular-docking-driven method for insulin delivery.

  2022cites this paper
• Individualisation of basal insulin therapy of type 2 diabetes: evidence from large randomized controlled trials

  2022cites this paper
• Glycaemic Control in People with Type 2 Diabetes Treated with Insulin Degludec: A Real-World, Prospective Non-interventional Study—UPDATES Saudi Arabia

  2022cites this paper
• Insulin Degludec Versus Insulin Glargine on Glycemic Variability in Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

  2022cites this paper
• The Experience of our Center in Patients Undergoing Insulin Degludec/Insulin Aspart Co-Formulation Therapy.

  2022cites this paper
• Series: Cardiovascular outcome trials for diabetes drugs.

  2022cites this paper
• One-year safety and effectiveness of insulin degludec in patients with diabetes mellitus in routine clinical practice in India—TRUST (Tresiba real-world use study)

  2022cites this paper
• Twenty Years of Insulin Gla-100: A Systematic Evaluation of Its Efficacy and Safety in Type 2 Diabetes Mellitus

  2022cites this paper
• Effect of Peptide Drug Liraglutide Nano-Formulation Combined with Sodium-Glucose Cotransporter-2 Inhibitor on Blood Lipids in Patients with Type 2 Diabetes.

  2022cites this paper
• 2022 update to the position statement by Primary Care Diabetes Europe: a disease state approach to the pharmacological management of type 2 diabetes in primary care.

  2022cites this paper
• Abordaje integral de las personas con diabetes tipo 2. Área de Conocimiento de Diabetes de la Sociedad Española de Endocrinología y Nutrición

  2022cites this paper
• Impact of frailty metabolic phenotypes on the management of older people with type 2 diabetes mellitus

  2021cites this paper
• Practical guidance on the initiation, titration, and switching of basal insulins: a narrative review for primary care

  2021cites this paper
• Series: Cardiovascular outcome trials for diabetes drugs Degludec and DEVOTE

  2021cites this paper
• Clinical research of insulin glargine U300 basal‐bolus therapy and insulin degludec/aspart co‐formulation in type 2 diabetes mellitus: A real world experience

  2021cites this paper
• Efficacy and safety of insulin degludec in renal transplant recipients with pre-existing diabetes

  2021cites this paper
• Duration of type 2 diabetes does not appear to moderate hypoglycaemia rate with insulin degludec versus insulin glargine U100

  2021cites this paper
• Evaluating the Effectiveness of Switching to Insulin Degludec from Other Basal Insulins in a Real-World Canadian Population with Type 1 or Type 2 Diabetes: The CAN-TREAT Study

  2021cites this paper
• Hundert Jahre – Insulin bleibt aktuell und notwendig

  2021influential citation
• Delphi-Based Consensus on Treatment Intensification in Type 2 Diabetes Subjects Failing Basal Insulin Supported Oral Treatment: Focus on Basal Insulin + GLP-1 Receptor Agonist Combination Therapies

  2021cites this paper
• Effect of insulin degludec versus insulin glargine U100 on time in range: SWITCH PRO, a crossover study of basal insulin‐treated adults with type 2 diabetes and risk factors for hypoglycaemia

  2021influential citation
• Real-world study on the effectiveness and safety of basal insulin IDegLira in type 2 diabetic patients previously treated with multi-injective insulin therapy.

  2021cites this paper
• Insulin Pump Therapy: Yesterday, Today and Tomorrow

  2021cites this paper
• Trends in basal insulin prescribing in older adults with chronic kidney disease in Ontario, Canada: A population‐based analysis from 2010 to 2020

  2021cites this paper
• 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022.

  2021cites this paper
• Hypoglycemia in type 2 diabetes

  2021cites this paper
• Optimal Type 2 Diabetes Mellitus Management and Active Ageing

  2021cites this paper
• Nocturnal hypoglycemia in type 1 and type 2 diabetes: an update on prevalence, prevention, pathophysiology and patient awareness

  2021cites this paper
• The ongoing evolution of basal insulin therapy over 100 years and its promise for the future

  2021cites this paper
• Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.

  2021cites this paper
• Comparing the reporting and conduct quality of exercise and pharmacological randomised controlled trials: a systematic review

  2021cites this paper
• Identification of the Inappropriate Clinical Actions (DON'T) to Improve the Management of Patients with Type 2 Diabetes Failing Basal Insulin Supported Oral Treatment: Results of Survey for a Panel of Diabetes Specialists in Italy

  2021cites this paper
• L’insulinothérapie chez les personnes âgées diabétiques de type 2 : l’éclairage de l’étude Gérodiab

  2021cites this paper
• Degludec hospital trial: A randomized controlled trial comparing insulin degludec U100 and glargine U100 for the inpatient management of patients with type 2 diabetes

  2021cites this paper
• A Review on Basal Bolus Regimen in Type 1 and Type 2 Diabetes Mellitus.

  2020cites this paper
• Target attainment in insulin-naive patients at high risk for hypoglycemia: Results from ACHIEVE Control.

  2020cites this paper
• Improving the treatment of patients with diabetes using insulin analogues: current findings and future directions

  2020cites this paper
• Stellenwert der Insulintherapie bei Diabetes Typ 2

  2020cites this paper
• 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2021.

  2020cites this paper
• Real-world cost-effectiveness of insulin degludec in type 1 and type 2 diabetes mellitus from a Swedish 1-year and long-term perspective

  2020cites this paper
• Diabetes mellitus type 2 in adults

  2020cites this paper
• Considerations for Insulin-Treated Type 2 Diabetes Patients During Hospitalization: A Narrative Review of What We Need to Know in the Age of Second-Generation Basal Insulin Analogs

  2020cites this paper
• The Safety and Efficacy of Second-Generation Basal Insulin Analogues in Adults with Type 2 Diabetes at Risk of Hypoglycemia and Use in Other Special Populations: A Narrative Review

  2020cites this paper
• Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update.

  2020cites this paper
• Understanding the Clinical Profile of Insulin Degludec, the Latest Basal Insulin Approved for Use in Canada: a Narrative Review

  2020cites this paper
• IDegLira fixed-ratio combination in the real world: a retrospective observational single-center Italian experience.

  2020cites this paper
• Current status of insulin degludec in type 1 and type 2 diabetes based on randomized and observational trials.

  2020cites this paper
• Effects of insulin degludec and insulin glargine U300 on glycaemic stability in individuals with type 1 diabetes: A multicentre, randomized controlled crossover study

  2020cites this paper
• Pharmacologic Approaches to Glycemic Treatment of Type 2 Diabetes: Synopsis of the 2020 American Diabetes Association's Standards of Medical Care in Diabetes Clinical Guideline

  2020cites this paper
• Fixed-Ratio Combinations of Basal Insulin and Glp-1ra in the Management of Type 2 Diabetes Mellitus: Highlight from Literature.

  2020cites this paper
• Using 2nd generation basal insulins in type 2 diabetes: Costs and savings in a comparative economic analysis in Italy, based on the BRIGHT study.

  2020cites this paper
• Switching to Degludec is Associated with Reduced Hypoglycaemia, Irrespective of Definition Used or Patient Characteristics: Secondary Analysis of the ReFLeCT Prospective, Observational Study

  2020cites this paper
• Monitoring and management of hyperglycemia in patients with advanced diabetic kidney disease.

  2020cites this paper
• Pens and Needles

  2020cites this paper
• Second‐generation basal insulins to initiate insulin therapy in type 2 diabetes: A need for clinical evidence before incurring increased costs

  2020cites this paper
• The Clinical Role of Insulin Degludec/Insulin Aspart in Type 2 Diabetes: An Empirical Perspective from Experience in Australia

  2020cites this paper
• Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial

  2020cites this paper
• Reduced Rates of Hypoglycemia in Type 1 or Type 2 Diabetes After Switching to Insulin Degludec: Results from the Italian Cohort of the ReFLeCT Study

  2020cites this paper
• How Valid Are the New Hypoglycemia Definitions for Use in Clinical Trials?

  2020cites this paper
• Clinical Considerations When Initiating and Titrating Insulin Degludec/Liraglutide (IDegLira) in People with Type 2 Diabetes

  2020cites this paper
• Association of insulin regimens with severe hypoglycaemia in patients with type 1 diabetes: A Danish case–control study

  2020cites this paper
• Фармакоэкономическое сравнение аналогов инсулина второго поколения и препаратов на их основе

  2020cites this paper
• Recent Advances in Insulin Therapy

  2020influential citation
• Biosynthetic Human Insulin and Insulin Analogs.

  2020cites this paper